Chief Editor

Dr. A. Singaraj, M.A., M.Phil., Ph.D.

Managing Editor
Mrs.M.Josephin Immaculate Ruba
EDITORIAL ADVISORS
1. Prof. Dr.Said I.Shalaby, MD,Ph.D. ISSN (Online): 2455-7838
Professor & Vice President
Tropical Medicine, SJIF Impact Factor (2024):8.675
Hepatology & Gastroenterology, NRC, ISI I.F. Value : 1.241
Academy of Scientific Research and Technology,
Cairo, Egypt. DOI : 10.36713/epra2016
2. Dr. Mussie T. Tessema,
Associate Professor,
Department of Business Administration,
Winona State University, MN, EPRA International Journal of
United States of America,
3. Dr. Mengsteab Tesfayohannes,
Associate Professor,
Department of Management,
Research &
Sigmund Weis School of Business,
Susquehanna University,
Selinsgrove, PENN,
Development
United States of America,
4. Dr. Ahmed Sebihi
(IJRD)
Associate Professor
Faculty of General Education,
Monthly Peer Reviewed & Indexed
Skyline University College (SUC), International Online Journal
University City of Sharjah,
UAE.
5. Dr. Anne Maduka, Volume: 9, Issue:12,December 2024
Assistant Professor,
Department of Economics,
Anambra State University, Indexed By:
Igbariam Campus,
Nigeria.
6. Dr. D.K. Awasthi, M.SC., Ph.D.
Associate Professor
Department of Chemistry,
Sri J.N.P.G. College,
Charbagh, Lucknow,
Uttar Pradesh. India
7. Dr. Tirtharaj Bhoi, M.A, Ph.D,
Assistant Professor,
School of Social Science,
University of Jammu,
Jammu, Jammu & Kashmir, India.
8. Dr. Pradeep Kumar Choudhury,
Assistant Professor,
Institute for Studies in Industrial Development,
An ICSSR Research Institute,
New Delhi- 110070, India.
9. Dr. Gyanendra Awasthi, M.Sc., Ph.D., NET
Associate Professor & HOD
Department of Biochemistry,
Dolphin (PG) Institute of Biomedical & Natural
Sciences,
Dehradun, Uttarakhand, India.
10. Dr. C. Satapathy,
Published By
Director,
Amity Humanity Foundation, EPRA Publishing
Amity Business School, Bhubaneswar, CC License
Orissa, India.
11. Dr. Ibatova Shoira Mavlanovna PhD.
Department of Propaedeutics of Paediatric
Diseases, Samarkand State Medical University

,,
 SJIF Impact Factor (2024): 8.675| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 9 | Issue: 12 | December 2024 - Peer Reviewed Journal

HERBAL DRUGS: ROLE IN THE TREATMENT OF CANCER

Rushiraj Ramkrishna Jodave1, Aviraj Baliram Jambhale2, Dinesh Raju Bamane3,

Pradnya Ankush Khelbude4, Nandini Hotkar5
Lokmangal College of Pharmacy, Wadala,Solapur, Maharashtra, India -413222

ABSTRACT
Cancer encompasses a collection of diseases marked by the unrestrained growth and spread of abnormal cells. When this growth
unchecked, it may lead to tumors, harm to bodily tissues, and the dissemination (metastasis) to various other areas of the body. There
are numerous cancer types, such as breast cancer, lung cancer, prostate cancer, skin cancer, each different regions. Typically, cancer
originates from genetic mutations that interfere with normal cellular regulation, prompting cells to multiply uncontrollably. These
mutations may be inherited, triggered by environmental influences (including smoking, radiation, or exposure to cancer-causing
agents), or they can occur spontaneously. Treatment alternatives vary based on the cancer type and stage, potentially involving surgery,
chemotherapy, radiation therapy, immunotherapy, and targeted therapies. Detecting cancer early through screenings can significantly
enhance the prospects for effective treatment. Synthetic drugs for cancer therapy aim to precisely focus on cancer cells, prevent tumor
advancement, or enhance the body’s immune system in combating the disease. Herbal medicines, sourced from natural plants, have
been utilized in traditional medicine for centuries and are increasingly recognized in contemporary healthcare due to their potential
healing properties. These natural substances provide a broad array of pharmacological advantages, such as antioxidant, anti-
inflammatory, antimicrobial, and anticancer effects. Their capacity to influence various biological pathways makes them essential in
managing intricate conditions, including cancer, heart diseases, and neurodegenerative disorders.
KEYWORDS: Cancer, Herbal drugs, Treatment.

INTRODUCTION
The growing burden of cancer globally underscores the need for novel, effective, and safer treatment options. Herbal drugs, derived
from medicinal plants, have emerged as a valuable resource in cancer therapy due to their diverse bioactive compounds with
anticancer, antioxidant, and anti-inflammatory properties. These natural agents act through mechanisms such as inducing apoptosis,
inhibiting angiogenesis, modulating immune responses, and suppressing cancer cell proliferation. Unlike conventional therapies,
herbal drugs often exhibit lower toxicity and fewer side effects, making them attractive as complementary or alternative treatments
[1].
Medicinal plants have been essential to healthcare for centuries and have formed the basis of many contemporary pharmaceuticals.
Recently, there has been a growing interest in plant-based treatments for cancer due to an increasing desire for alternative and
complementary medicine options. Cancer, known for its complexity and varied nature, often necessitates treatments that are both
effective and cause fewer side effects. Numerous medicinal plants possess bioactive compounds with properties that combat cancer,
such as alkalo, flavonoids, and terpenoids, which have demonstrated effectiveness in slowing cancer cell proliferation, promoting
apoptosis, and hindering metastasis. Ongoing research is investigating these natural compounds for their potential to improve
standard cancer therapies or act as independent treatments. As the quest for safer and more effective cancer treatments progresses,
medicinal plants continue to be a vital asset in oncology studies. This review intends to emphasize significant medicinal plants that
are utilized in cancer treatment and the mechanisms through which they operate [2].

Current Approaches for the Treatment of Cancer

The treatment of cancer has evolved significantly over the years, with modern approaches focusing on improving efficacy, precision,
and patient quality of life. Current strategies include:
Surgical removal of tumors is often the first step for localized cancers. Advances in minimally invasive and robotic-assisted surgeries
have enhanced precision and recovery outcomes.

High-energy radiation, such as X-rays or protons, targets and destroys cancer cells by damaging their DNA. Techniques like
intensity-modulated radiation therapy (IMRT) and proton beam therapy improve accuracy and reduce side effects.

Chemotherapy uses cytotoxic drugs to destroy rapidly dividing cancer cells. It is often used in combination with other treatments
but can lead to side effects such as nausea, fatigue, and immune suppression.

2024 EPRA IJRD | Journal DOI: https://doi.org/10.36713/epra2016 | https://eprajournals.com/ |8 |

 SJIF Impact Factor (2024): 8.675| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 9 | Issue: 12 | December 2024 - Peer Reviewed Journal

Targeted Therapy focuses on specific molecular targets involved in cancer cell growth and survival. Examples include monoclonal
antibodies and small-molecule inhibitors, such as trastuzumab (for HER2-positive breast cancer) and imatinib (for chronic myeloid
leukemia).

Immunotherapy enhances the body’s immune system to recognize and attack cancer cells. Immune checkpoint inhibitors (e.g.,
pembrolizumab) and CAR-T cell therapy represent significant advances in treating certain cancers [3, 4].

Hormonal Therapy is used for cancers driven by hormones, such as breast and prostate cancer. Drugs like tamoxifen and aromatase
inhibitors block or lower hormone levels to slow tumor growth.

Bone Marrow and Stem Cell Transplantation involves replacing damaged bone marrow with healthy stem cells, often after high-
dose chemotherapy or radiation. This is used for blood cancers such as leukemia and lymphoma.

The integration of advanced technologies, such as artificial intelligence and genomics, continues to refine allopathic cancer
treatments, making them more precise and patient-centric [5].

Limitations of Allopathic Approaches for the Treatment of Cancer

While allopathic treatments for cancer have significantly improved patient outcomes, they are associated with several limitations
that can impact their effectiveness, safety, and accessibility:

Toxicity and Side Effects

Chemotherapy and Radiation Therapy: These treatments often damage healthy tissues alongside cancer cells, leading to side effects
such as nausea, fatigue, immune suppression, hair loss, and long-term complications (e.g., secondary cancers).
Targeted and Immunotherapy: While more precise, they can still cause adverse reactions, such as immune-related side effects or
organ inflammation.

Drug Resistance
Cancer cells can develop resistance to chemotherapy, targeted therapies, and immunotherapies, reducing their efficacy over time.
This often necessitates a shift to alternative treatments, which may be less effective.

Incomplete Response
Not all patients respond adequately to standard treatments. Factors such as genetic heterogeneity of tumors and variations in
individual biology can limit treatment success [6-8].

High Costs and Accessibility

Advanced therapies like CAR-T cell therapy, proton beam therapy, and precision medicine can be prohibitively expensive, limiting
access for many patients, especially in low-resource settings.

Risk of Recurrence
Some treatments may not eliminate all cancer cells, leading to a risk of recurrence. This is particularly challenging in aggressive or
metastatic cancers.

Limited Efficacy for Advanced or Metastatic Cancers

Allopathic treatments are often less effective for cancers that are advanced or have spread extensively, where options are limited to
palliative care or experimental therapies.

Potential for Over-treatment

In some cases, aggressive treatments may be used even when the expected benefits are minimal, leading to unnecessary side effects
and reduced quality of life.

Resistance to Immunotherapies
Some tumors evade immune system detection or create an immunosuppressive microenvironment, making immunotherapy less
effective.

Long-term Health Risks

Treatments like radiation and chemotherapy can lead to chronic health problems, such as cardiovascular issues, infertility, or
secondary malignancies, long after the treatment ends [9, 10].

2024 EPRA IJRD | Journal DOI: https://doi.org/10.36713/epra2016 | https://eprajournals.com/ |9 |

 SJIF Impact Factor (2024): 8.675| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 9 | Issue: 12 | December 2024 - Peer Reviewed Journal

Importance of Herbal Drugs

Herbal medicines have garnered significant attention in the field of cancer, primarily due to their ability to offer therapeutic benefits
with fewer adverse effects compared to standard chemotherapy and radiation therapies. The active compounds present in various
herbs, including flavonoids, alkaloids, saponins, and terpenes, showcase a range of pharmacological properties, such as anti-
inflammatory, antioxidant, and anti-tumor effects. These compounds can block cancer cell growth, trigger apoptosis (the process of
programmed cell death), impede angiogenesis (the creation of new blood vessels that nourish tumors), and diminish metastasis (the
distribution of cancer cells to other parts of the body).

Numerous herbal treatments function by influencing molecular pathways that play a role in cancer development. For instance,
curcumin (derived from Curcuma longa), resveratrol (found in grapes), and epigallocatechin gallate (EGCG from green tea) have
shown the capacity to disrupt cell signaling pathways that are essential for the survival and multiplication of cancer cells.
Furthermore, particular herbal solutions can enhance immune system activity, aiding the body in identifying and eliminating cancer
cells more efficiently.

Herbal drugs are often used in combination with conventional treatments to enhance efficacy, reduce toxicity, and improve the
quality of life for cancer patients. While some herbs are being integrated into modern oncological practices, ongoing research and
clinical trials are necessary to validate their effectiveness and ensure safety. In the future, herbal drugs may play an even more
prominent role in integrative cancer therapy, offering new avenues for treatment and prevention [11].

Merits of Herbal Drugs

Herbal drugs are rich in bioactive compounds such as alkaloids, flavonoids, terpenoids, and polyphenols, which have been shown
to possess anti-cancer properties. These compounds can inhibit cancer cell growth, induce apoptosis (cell death), and prevent the
spread (metastasis) of tumors.

Compared to conventional chemotherapy and radiation, herbal drugs tend to have lower toxicity. Many cancer treatments cause
severe side effects such as nausea, fatigue, and organ damage. Herbal drugs often provide a gentler alternative or complement by
targeting cancer cells while sparing healthy tissue [11].

Herbal drugs often act on multiple biological pathways simultaneously, which can be beneficial in treating cancer, a disease known
for its complex mechanisms. For example, they can inhibit tumor growth, reduce inflammation, suppress angiogenesis (formation
of blood vessels in tumors), and boost immune response [12].

Herbal compounds can work synergistically, meaning that when combined, their therapeutic effects are enhanced. This property is
often used to develop multi-component herbal formulations that may be more effective than single-compound treatments.

Many herbs have been found to have chemo preventive properties, meaning they can help in preventing the initiation, promotion,
and progression of cancer. By neutralizing free radicals and reducing oxidative stress, herbal drugs can minimize DNA damage and
the risk of mutations that lead to cancer [13].

Herbal drugs are also used in palliative care to improve the quality of life for cancer patients. They can alleviate side effects of
conventional treatments (such as nausea, pain, and fatigue), enhance physical well-being, and support emotional health.

Herbal drugs are often more affordable compared to modern pharmaceutical treatments, making them accessible to a broader range
of patients, especially in developing countries where traditional medicine is more prevalent.

Some cancer cells develop resistance to conventional chemotherapy drugs. Certain herbal compounds have been found to help
overcome this resistance by altering cellular mechanisms, potentially making cancer treatments more effective over time.
Herbal drugs offer a promising and holistic approach to cancer treatment by providing natural compounds with therapeutic effects,
fewer side effects, and the ability to target multiple mechanisms involved in cancer progression. Their integrative use alongside
conventional treatments continue to be an area of active research [14-16].

2024 EPRA IJRD | Journal DOI: https://doi.org/10.36713/epra2016 | https://eprajournals.com/ |10 |

 SJIF Impact Factor (2024): 8.675| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 9 | Issue: 12 | December 2024 - Peer Reviewed Journal

Table no.1: List of medicinal plants used for the treatment mitigation and prevention of cancer
Sr. Plant Phytochemical Anticancer activity into the
no. chemical compound
1 Adiantum venustrum Terpenoids, Flavonoid Reduction in lipid peroxidation
2 Aloe vera Aloin Inhibition of human
neuroectodermal tumors
3 Heart-leaved moonseed alkaloids, glycosides, steroids, antiproliferative
4 Zingiber officinale 6-gingerol and 6-shogaol inhibit the activation of NF-κB
and MAPK signalling
5 Turmeric Curcuminoids inhibiting cell proliferation
promoting cell apoptosis

DETAILS REGARDING THE HERBAL PLANTS

Adiantum Venustrum
Kingdom Plantae
Family Pteridaceae
Subfamily Vittarioideae
Class Polypodiopsida
Division Tracheophyta
Species Venustum
Order Polypodiales
Genus Adiantum

Anti-Cancer Activity
Induction of Apoptosis: Certain compounds may trigger programmed cell death in cancer cells while sparing normal cells.
Anti-inflammatory Effects: Reducing inflammation can lower the risk of cancer progression, and compounds in the fern may
contribute to this effect.

While preliminary findings are promising, more extensive studies, including clinical trials, are needed to fully understand the
anticancer potential of Adiantum venustrum. Investigating its active compounds and mechanisms will be crucial for validating its
use in cancer therapy [17].

Aloe Vera
Kingdom Plantae
Family Asphodelaceae
Subfamily Asphodeloideae
Class Liliopsida
Division Magnoliophyta - Flowering plants
Species Succulen
Order Asparagales
Genus Aloe

Anti-Cancer Activity
Aloe-emodin inhibited the proliferation of Merkel Cells Carcinoma to a significant degree and has also anti-neuroectodermal tumour
activity in vitro and in vivo. Anthraquinones are involved in induction of death of human cancer cells in many studies. In Egypt, it
was demonstrated that the extracts of Aloe Vera could have anti-hepatocarcinogenic effect through modulation of apoptosis [18, 19].

Heart-Leaved Moonseed
Kingdom Plantae
Family Menispermaceae
Class Magnoliopsida
Species Cordifolia
Order Ranunculales

Anti-Cancer Activity

2024 EPRA IJRD | Journal DOI: https://doi.org/10.36713/epra2016 | https://eprajournals.com/ |11 |

 SJIF Impact Factor (2024): 8.675| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 9 | Issue: 12 | December 2024 - Peer Reviewed Journal

Cancer is one of the main reasons for death among women all around the world. In a study, HCl extract of T. cordifolia roots was
exposed to liver and extra hepatic organs of rats, at concentration levels of 50 and 100mg/kg of body weight. A significant increase
in Glutathione and other metabolizing enzymes levels was observed. Furthermore, malonaldehyde (MLD) level was decreased. In
another study, the effect of T. cordifolia hexane extract on rats having Ehrlich ascites tumor was examined. Inhibition of proliferation
of tumor cell (G1 phase) was observed and at the same time the ‘Bax’ gene expression was enhanced. The anticancer properties of
secondary metabolites including yangambin, palmatine and magnoflorine extracted from T. cordifolia were tested tested in different
types of tumor cells. Palmatine and yangambin were highly effective against oral cancerous cells, while others were effective against
colon cancer cells. Synthetic chemotherapeutic agents have adverse effects on health, which is not the case with T. cordifolia.
Therefore, it can be used as a safe drug to cure cancer disease [20, 21].

Zingiber Officinale
Kingdom Plantae
Family Zingiberaceae
Subfamily Zingiberoideae
Division Magnoliophyta
Order Zingiberales
Genus Zingiber

Anti-Cancer Activity
Activation of Caspases
Ginger compounds can activate caspases, a family of proteases that play essential roles in programmed cell death. This activation
leads to a cascade of reactions that ultimately result in cellular apoptosis.

Modulation of Bcl-2 Family Proteins

Ginger influences the expression of proteins in the Bcl-2 family, which regulate apoptosis. For example, it may downregulate anti-
apoptotic proteins like Bcl-2 and upregulate pro-apoptotic proteins like Bax, promoting the release of cytochrome c from the
mitochondria and triggering the apoptotic pathway.

Inhibition of NF-κB Pathway

Ginger can inhibit the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway, which is often activated in
cancer cells and promotes cell survival. By suppressing this pathway, ginger can enhance apoptosis.

Reactive Oxygen Species (ROS) Generation

Some studies suggest that ginger induces ROS production, which can lead to oxidative stress and damage cellular components,
pushing the cells towards apoptosis.

Cell Cycle Arrest

Ginger can cause cell cycle arrest at various phases (often at the G0/G1 phase), which can lead to apoptosis. This arrest prevents
cancer cells from proliferating and allows time for damaged cells to undergo programmed cell death.

Death Receptor Pathway Activation

Ginger may enhance the expression of death receptors (such as Fas) on the surface of cancer cells, facilitating the extrinsic apoptotic
pathway that is triggered by ligands binding to these receptors [22-24].

Turmeric
Kingdom Plantae
Family Zingiberaceae
Subfamily Zingiberoideae
Class Liliopsida
Division Angiosperm
Order Zingiberales
Genus Curcuma

Anti-Cancer Activity
Inhibition of Cancer Cell Proliferation
Cell Cycle Regulation: Curcumin has been shown to arrest the cell cycle at different phases (G1, S, or G2/M) in cancer cells. By
preventing cancer cells from dividing, curcumin can reduce tumor growth. This action is believed to occur through modulation of
key regulatory proteins such as cyclins and cyclin-dependent kinases (CDKs), which control the progression of the cell cycle.
2024 EPRA IJRD | Journal DOI: https://doi.org/10.36713/epra2016 | https://eprajournals.com/ |12 |
 SJIF Impact Factor (2024): 8.675| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 9 | Issue: 12 | December 2024 - Peer Reviewed Journal

Downregulation of Oncogenes: Curcumin can suppress the expression of genes involved in the proliferation of cancer cells, such as
Myc, K-ras, and EGFR (epidermal growth factor receptor) [25-27].

REFERENCES
1. Hasanpoor Dehkordi A, Azari S. Quality of life and related factor in cancer patients. Behbood. 2006;10(2):110–119.
2. Tabari F, Zakeri Moghadam M, Bahrani N, Monjamed Z. Evaluation of the Quality of Life in newly Recognized Cancer Patients.
HAYAT. 2007;13(2):5–12.
3. Mardani Hamule M, Shahraky Vahed A. The Assessment of Relationship between Mental Health and Quality of Life in Cancer Patients.
Scientific Journal of Hamadan University of Medical Sciences. 2009;16(2):33–38.
4. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59:225–249. doi:
10.3322/caac.20006.
5. MacMahon B. Cigarette smoking and cancer of the breast. In: Wald N, Baron J, editors. Smoking and hormone related disorders. Oxford:
Oxford University Press; 1990. pp. 154–166.
6. Luo J, Solimini NL, Elledge SJ. (2009). Principles of cancer therapy: oncogene and nononcogene addiction. Cell, 136(5):823–37.
7. Sudhakar A. (2009). History of cancer, ancient and modern treatment methods. J Cancer Sci Ther, 1(2):1–4.
8. Van Dyke T, Jacks T. (2002). Cancer modeling in the modern era: progress and challenges. Cell, 108(2):135–44.
9. Upadhyay A. Cancer: An unknown territory; rethinking before going ahead. Genes Dis. 2020 Sep 18;8(5):655-661.
10. Lambert A.W., Pattabiraman D.R., Weinberg R.A. Emerging biological principles of metastasis. Cell. 2017;168(4):670–691.
11. Mroz E.A., Rocco J.W. The challenges of tumor genetic diversity. Cancer. 2017;123(6):917–927.
12. Hanselmann R.G., Welter C. Origin of cancer: an information, energy, and matter disease. Front Cell Dev Biol. 2016;4 doi:
10.3389/fcell.2016.00121.
13. Greaves M. Evolutionary determinants of cancer. Canc Discov. 2015;5(8):806–820. doi: 10.1158/2159-8290.CD-15-0439.
14. Palumbo M.O., Kavan P., Miller W.H. Jr. Systemic cancer therapy: achievements and challenges that lie ahead. Front Pharmacol. 2013;4
doi: 10.3389/fphar.2013.00057.
15. Turnbull A.K. Personalized medicine in cancer: where are we today? Future Oncol. 2015;11(20):2795–2798. doi: 10.2217/fon.15.204.
16. Wheeler H.E., Maitland M.L., Dolan M.E., Cox N.J., Ratain M.J. Cancer pharmacogenomics: strategies and challenges. Nat Rev Genet.
2013;14(1):23–34. doi: 10.1038/nrg3352.
17. Viral D, Shivanand P, Jivani N. Anticancer Evaluation of Adiantum venustum Don. J Young Pharm. 2011 Jan;3(1):48-54.
18. Manirakiza A, Irakoze L, Manirakiza S. Aloe and its Effects on Cancer: A Narrative Literature Review. East Afr Health Res J.
2021;5(1):1-16.
19. Gao Y, Kuok KI, Jin Y, Wang R. Biomedical applications of Aloe vera. Crit Rev Food Sci Nutr. 2018;1–13 Medline.
20. Aher V, Wahi A (2011) Biotechnical approach to evaluate immunomodulatory activity of ethanolic extract of Tinospora cordifolia stem
(mango plant climber). Iran J Pharm Res 3:863–872.
21. Aher V, Wahi A (2011) Biotechnical approach to evaluate immunomodulatory activity of ethanolic extract of Tinospora cordifolia stem
(mango plant climber). Iran J Pharm Res 3:863–872.
22. Kim J.S, Lee S.I, Park H.W, editors. Cytotoxic components from the dried rhizomes of Zingiber offici-naleRoscoe. Arch Pharm
Res. 2008;31:415–8.
23. Ahmed R.S, Suke S.G, Seth V, Chakraborti A, Tripathi A.K, Banerjee B.D. Protective effects of dietary ginger (Zingiber officinales
Rosc.) on lindane-induced oxidative stress in rats. Phytother Res. 2008;22:902–6.
24. Bidinotto L.T, Spinardi-Barbisan A.L, Rocha N.S, Salvadori D.M, Barbisan L.F. Effects of ginger (Zingiber officinale Roscoe) on DNA
damage and development of urothelial tumors in a mouse bladder carcinogenesis model. Environ Mol Mutagen. 2006;47:624–30.
25. Aggarwal B.B. Targeting inflammation-induced obesity and metabolic diseases by curcumin and other neutraceuticals. Annu Rev
Nutr. 2010;30:173–199. Epub, Apr 26.
26. Aruna K, Sivaramakrishnan V.M. Plant products as protective agents against cancer. Indian J Exp Biol. 1990;28:1008–11.
27. Aruna K, Rukkumani R, Menon V.P. Role of Cuminum cyminum on ethanol and preheated sunflower oil induced lipid peroxidation. J
Herbs Spices Med Plants. 2005;11:103–14.

2024 EPRA IJRD | Journal DOI: https://doi.org/10.36713/epra2016 | https://eprajournals.com/ |13 |